title: Effect of the calcium phosphate-mediated RNA uptake on the transfer of cellular immunity of a synthetic peptide of HIV-1 to human lymphocytes by exogenous RNA.
abstract: It is known that exogenous RNA molecules can be taken up by eukaryotic cells and can exert a variety of biological effects both in vitro and in vivo. The modulation of human lymphocytes by exogenous RNAs has medical implications. The exogenous RNA used in this study was obtained from lymphoid organs of animals immunized with the synthetic peptide p12 of HIV-1 and was referred to as p12-RNA. Human lymphocytes were transfected with the p12-RNA and the transfer of immunoreactivity of p12 was assessed by the lymphocyte proliferation and the leukocyte adherence inhibition assays. Our results indicate that the transfer of cellular immune response to the p12 occurred in 9 donors (60%) who were named responsive individuals whereas 6 donors (40%) were non-responsives. We also found that the calcium phosphate-mediated RNA uptake method is effective in converting non-responsive into responsive donors. The calcium phosphate-mediated RNA uptake may also be used to increase the efficiency of RNA transfection in other models with medical implications and to contribute to a better understanding of the molecular events involved in the uptake of RNA. Our findings give support for the use of exogenous RNAs obtained from lymphoid organs of immunized animals with synthetic peptides of HIV-1 in the immune reconstitution of individuals infected with HIV-1.
authors.affiliation: Department of Biochemistry and Immunology, School of Medicine University of São Paulo, Ribeirão Preto, Brazil. fldlucca@fmrp.usp.br
authors.forename: F L
authors.initials: FL
authors.lastname: De Lucca
authors.forename: F M
authors.initials: FM
authors.lastname: Sawan
authors.forename: M A
authors.initials: MA
authors.lastname: Watanabe
authors.forename: L R
authors.initials: LR
authors.lastname: de Souza
mesh_terms: D000818:Animals; D002130:Calcium Phosphates / Q000494:pharmacology*; D002478:Cells, Cultured; D006168:Guinea Pigs; D019302:HIV Envelope Protein gp160 / Q000235:genetics / Q000276:immunology*; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007111:Immunity, Cellular; D007117:Immunization, Secondary; D007957:Leukocyte Adherence Inhibition Test; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology*; D008546:Melanoma, Experimental / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D009842:Oligopeptides / Q000235:genetics / Q000276:immunology*; D012313:RNA / Q000276:immunology*; D014162:Transfection; D016896:Treatment Outcome
chemical_list: D002130:Calcium Phosphates; D019302:HIV Envelope Protein gp160; D009842:Oligopeptides; C013674:RNA, immune; C485828:alpha-tricalcium phosphate; C485830:tetracalcium phosphate; D012313:RNA; C485838:calcium phosphate, monobasic, anhydrous; C020243:calcium phosphate; C485829:calcium phosphate, dibasic, anhydrous